Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2009; 54:1123-1130, doi:10.1016/j.jacc.2009.04.089
© 2009 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correction (v54,p1635)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Al Jaroudi, W.
Right arrow Articles by Iskandrian, A. E.
PubMed
Right arrow Articles by Al Jaroudi, W.
Right arrow Articles by Iskandrian, A. E.
Related Collections
Right arrowRelated Article

STATE-OF-THE-ART PAPER

Regadenoson: A New Myocardial Stress Agent

Wael Al Jaroudi, MD* and Ami E. Iskandrian, MD

Division of Cardiovascular Diseases, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama

Manuscript received January 22, 2009; revised manuscript received March 10, 2009, accepted April 26, 2009.

* Reprint requests and correspondence: Dr. Wael Al Jaroudi, 701 19th Street, LHRB 306, Birmingham, Alabama 35294 (Email: waljaroudi{at}cardmail.dom.uab.edu).

Vasodilator stress myocardial perfusion imaging (MPI) accounts for up to 50% of all stress MPI studies performed in the U.S. In 2008, the Food and Drug Administration approved regadenoson for stress testing in conjunction with MPI. Regadenoson, unlike adenosine, is a selective A2A agonist that is given as an intravenous bolus at a fixed dose, with less undesirable side effects including atrioventricular block and bronchospasm. Unlike adenosine, regadenoson could be used in patients with mild-to-moderate reactive airway disease. This review will summarize the pre-clinical and clinical data on regadenoson, as they specifically relate to its use as a vasodilator stress agent, currently the only approved selective A2A agonist.

Key Words: adenosine • regadenoson • myocardial perfusion imaging • single-photon emission computed tomography • stress testing

Abbreviations and Acronyms
  COPD = chronic obstructive pulmonary disease
  FDA = Food and Drug Administration
  FEV1 = forced expiratory volume (1 s)
  LV = left ventricle/ventricular
  MBF = myocardial blood flow
  MPI = myocardial perfusion imaging


Related Article

Inside This Issue
J. Am. Coll. Cardiol. 2009 54: A27. [Full Text] [PDF]





 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement